Faculty profile

John Kuruvilla

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

John Kuruvilla

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
81 publications in the last five years, latest in 2026.
Senior (last) author on 18 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.
Supervisor on 1 trainee award (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

188

Publications

1,426

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Lymphoma Research Consortium Strategic Planning Cancer-Related Cognitive Impairment Functioning Non-Hodgkin Lymphoma Psychosocial Return To Work

Latest papers

Dyadic Coping in Patients With Hematologic Malignancies and Their Partners: A Scoping Review.
Cancer nursing · 2026
Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.
Leukemia & lymphoma · 2026 · senior author
A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).
Blood neoplasia · 2026 · senior author

All 188 publications

Latest funding

Immuno-metabolomic biomarkers predictive of response to chimeric antigen T cell receptor therapy for B cell lymphoma
CIHR · 2024 · Supervisor
$140,000
Building a platform for advancing Canadian science in lymphoma: A strategic planning workshop of the Canadian Lymphoma Consortium (CLyC)
CIHR · 2022 · Principal investigator
$10,000
Trajectories of Psychosocial and Functional Outcomes among Non-Hodgkin Lymphoma (NHL) Survivors
CIHR · 2020 · Principal investigator
$260,100

All 5 grants and awards

From the 150 most recent of 188 publications.

Dyadic Coping in Patients With Hematologic Malignancies and Their Partners: A Scoping Review.

Hwang D, Malakian A, Kuruvilla J, Jibb LA, Nissim R, Mayo SJ

Cancer nursing2026

DOI: 10.1097/ncc.0000000000001635 PMID: 42745270

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Gong IY, Xiao NM, Chen C, Bhella S, Hueniken K, Marinoni M, Azab M, Aoki T, Kridel R, Kukreti V, Vijenthira A, Yang C, Rodin D, Jeeva M, Aminilari M, Malik N, Wells W, Hodgson D, Crump M, Prica A, Kuruvilla J

Leukemia & lymphoma2026Senior author

DOI: 10.1080/10428194.2026.2682290 PMID: 42295978

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Assouline S, Prica A, Villa D, Kridel R, Johnson N, Kukreti V, Shamy A, Kaedbey R, Gerrie A, Savage K, Kelly J, Shepherd LE, Hay AE, Scott DW, Crump M, Chen BE, Kuruvilla J

Blood neoplasia2026Senior author

DOI: 10.1016/j.bneo.2026.100233 PMID: 42255257

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Puckrin R, Villa D, Fleury I, Larouche JF, Kuruvilla J

Current oncology (Toronto, Ont.)2026Senior author

DOI: 10.3390/curroncol33070426 PMID: 42505228

Detection and classification of lymphoma from cell-free methylome data.

Shelton VB, Alias M, Liu T, Zhao D, Alamilla P, Singhawansa A, Hong M, Zeng Y, Murad V, Alrekhais I, Metser U, Hodgson D, Aoki T, Prica A, Kuruvilla J, Crump M, Lam B, Hoffman MM, Bratman SV, Kridel R

NPJ precision oncology2026

DOI: 10.1038/s41698-026-01533-8 PMID: 42236545

Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.

Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M, Kharfan-Dabaja MA

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.05.022 PMID: 40555394

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Bartlett NL, Sehn LH, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Sabalvaro F, Penuel E, Teodoro V, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE

American journal of hematology2026

DOI: 10.1002/ajh.70225 PMID: 41862428

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Aoki T, Duns G, Rai S, Jiang A, Lytle A, Yin Y, Kishida M, Yu Li M, Lee C, Smorra D, Hilton LK, Healy S, Alig SK, Shahrokh Esfahani M, Sarkozy C, Hung SS, Milne K, Telenius A, O'Brien L, Wong JCH, Cassidy C, Fujisawa M, Strong C, Goodyear T, Di Vito C, Luksik C, Edin G, Gonzalez L, Rangel Patiño J, Hong M, Wu S, Lee E, Sakhdari A, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng AP, Xu A, Merchant A, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Huntsman DG, Nelson BH, Farinha P, Morin RD, Alizadeh AA, Savage KJ, Scott DW, Steidl C

Cancer discovery2026

DOI: 10.1158/2159-8290.cd-25-0859 PMID: 41615883

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Gong IY, Kuruvilla J, Prica A, Olney H, Fraser G, Buckstein R, Skrabek P, Keating MM, Hay A, Shepherd L, Chen BE, Crump M

Blood advances2026

DOI: 10.1182/bloodadvances.2025018491 PMID: 41587423

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Kordbacheh T, Chan KKW, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D

Blood advances2026

DOI: 10.1182/bloodadvances.2025017401 PMID: 41544221

Something wrong or missing on this profile? Suggest a correction

John Kuruvilla

Research

Latest papers

Latest funding

Dyadic Coping in Patients With Hematologic Malignancies and Their Partners: A Scoping Review.

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Detection and classification of lymphoma from cell-free methylome data.

Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843.

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Immuno-metabolomic biomarkers predictive of response to chimeric antigen T cell receptor therapy for B cell lymphoma

Building a platform for advancing Canadian science in lymphoma: A strategic planning workshop of the Canadian Lymphoma Consortium (CLyC)

Trajectories of Psychosocial and Functional Outcomes among Non-Hodgkin Lymphoma (NHL) Survivors

Health Services for Lymphoma Survivors in Canada: A Patient-Oriented Stakeholder Consultation

Regulation of immunity by TNFR family members: from mechanisms of viral control to biomarkers of therapeutic outcome

Frequent collaborators

Robert Kridel

David Hodgson

Armand Keating

Danielle Rodin

Tony Panzarella

Christian Steidl

Wei Xu

Ralph Meyer

Tom Kouroukis

Ronan Foley

Mona Shafey

Irwin Ronald Walker

Kevin Imrie

Aly Karsan

Lisa Wang

Breffni Hannon

Tony Reiman

Ning Liu

Patrick Veit-Haibach

Lee Mozessohn

Jean Roy

David Lebrun

Tony Reiman

Gregory Pond

Beate Sander

Mark Minden

Nathalie Johnson

Camilla Zimmermann

Lucia Nappi

Tara Baetz

Rinat Nissim

Curtis Cooper

Kevin Hay

Stephanie Lheureux

Eric Winquist

Versha Banerji

Jan Delabie

Michael Reedijk

Jonathan Gubbay

Annette Hay